Table 4 Univariate and multivariate analysis of factors associated with sero-protection among children born to HBsAg-positive mothers in four provinces, China 2016–2017
Characteristics | No. of observations | Anti-HBs Positive | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|
n (%) | OR (95% CI) | P-value | aOR (95% CI) | P-value | ||
Maternal age (years) | ||||||
18–24 | 280 | 272 (97.1) | 1.0 (0.4–2.2) | 0.8 | ||
25–34 | 2992 | 2893 (96.7) | 0.8 (0.5–1.3) | |||
35–45 | 840 | 816 (97.1) | ||||
Maternal educational level | ||||||
Junior middle school or below | 1382 | 1341 (97.0) | 1.1 (0.8–1.6) | 0.6 | ||
High Middle school or above | 2730 | 2640 (96.7) | 1 | |||
Maternal residence rural / urban | ||||||
Rural | 2818 | 2731 (96.9) | 1.1 (0.8–1.6) | 0.6 | ||
Urban | 1294 | 1250 (96.6) | 1 | |||
Maternal parity | ||||||
1 | 1732 | 1679 (96.9) | 1.1 (0.8–1.5) | 0.7 | ||
> 1 | 2380 | 2302 (96.7) | 1 | |||
Maternal HBeAg status during this pregnancy | ||||||
Positive | 1221 | 1155 (94.6) | 0.4 (0.3–0.6) | < 0.001# | 0.4 (0.3–0.6) | < 0.001 |
Negative | 2740 | 2681 (97.8) | 1 | 1 | ||
Unknown | 151 | 145 (96.0) | 0.5 (0.2–1.3) | 0.6 (0.2–1.3) | 0.2 | |
Maternal antiviral treatment during this pregnancy | ||||||
Yes | 392 | 377 (96.2) | 0.8 (0.5–1.4) | 0.5 | ||
No | 3720 | 3604 (96.9) | 1 | |||
Level of delivery hospital | ||||||
Prefectural and above | 1518 | 1463 (96.4) | 0.8 (0.6–1.1) | 0.2 | ||
County level and below | 2594 | 2518 (97.1) | 1 | |||
Mode of delivery | ||||||
Vaginal delivery | 2349 | 2271 (96.7) | 0.9 (0.6–1.3) | 0.6 | ||
Caesarean section | 1763 | 1710 (97.0) | 1 | |||
Child gender | ||||||
Male | 2185 | 2118 (96.9) | 1.1 (0.8–1.5) | 0.6 | ||
Female | 1927 | 1863 (96.7) | 1 | |||
Gestational age (weeks) | ||||||
< 37 | 236 | 225 (95.3) | 0.7 (0.3–1.2) | 0.2 | ||
37–43 | 3876 | 3756 (96.9) | 1 | |||
Child birth weight (g) | ||||||
< 2500 | 131 | 122 (93.1) | 0.4 (0.2–0.9) | 0.02* | 0.4 (0.2–0.8) | 0.01 |
2500–5400 | 3981 | 3859 (96.9) | 1 | 1 | ||
Type of HBvacc-BD | ||||||
10 μg yeast vaccine | 3637 | 3520 (96.8) | 1.3 (0.6–2.7) | 0.4 | ||
20 μg CHO vaccine | 285 | 279 (97.9) | 2.0 (0.7–6.0) | |||
10 μg CHO vaccine | 190 | 182 (95.8) | 1 | |||
Interval between birth and HBvacc-BD (hours) | ||||||
Within 12 | 3579 | 3467 (96.9) | 1 | 0.5* | ||
12–24 | 466 | 450 (96.6) | 0.9 (0.5–1.5) | |||
> 24 | 67 | 64 (95.5) | 0.7 (0.2-2.2) | |||
Administered HBIG | ||||||
Yes | 4092 | 3961 (96.8) | 1.0 (0.96–0.97) | 1.0* | ||
No | 20 | 20 (100.0) | 1 | |||
Interval between 3rd dose HBvacc and HBV serological marker test (months) | ||||||
< 7 | 1666 | 1635 (98.1) | 2.2 (1.5–3.4) | < 0.001 | 2.2 (1.5–3.4) | < 0.001 |
7–18 | 2446 | 2346 (95.9) | 1 | 1 | ||